Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtre
1.
BMC Geriatr ; 22(1): 542, 2022 06 30.
Article Dans Anglais | MEDLINE | ID: covidwho-1910272

Résumé

BACKGROUND: Aging is one of the most important prognostic factors increasing the risk of clinical severity and mortality of COVID-19 infection. However, among patients over 75 years, little is known about post-acute functional decline. OBJECTIVE: The aim of this study was to identify factors associated with functional decline 3 months after COVID-19 onset, to identify long term COVID-19 symptoms and transitions between frailty statesafter COVID-19 onset in older hospitalized patients. METHODS: This prospective observational study included COVID-19 patients consecutively hospitalized from March to December 2020 in Acute Geriatric Ward in Nantes University Hospital. Functional decline, frailty status and long term symptoms were assessed at 3 month follow up. Functional status was assessed using the Activities of Daily Living simplified scale (ADL). Frailty status was evaluated using Clinical Frailty Scale (CFS). We performed multivariable analyses to identify factors associated with functional decline. RESULTS: Among the 318 patients hospitalized for COVID-19 infection, 198 were alive 3 months after discharge. At 3 months, functional decline occurred in 69 (36%) patients. In multivariable analysis, a significant association was found between functional decline and stroke (OR = 4,57, p = 0,003), history of depressive disorder (OR = 3,05, p = 0,016), complications (OR = 2,24, p = 0,039), length of stay (OR = 1,05, p = 0,025) and age (OR = 1,08, p = 0,028). At 3 months, 75 patients described long-term symptoms (49.0%). Of those with frailty (CFS scores ≥5) at 3-months follow-up, 30% were not frail at baseline. Increasing frailty defined by a worse CFS state between baseline and 3 months occurred in 41 patients (26.8%). CONCLUSIONS: This study provides evidence that both the severity of the COVID-19 infection and preexisting medical conditions correlates with a functional decline at distance of the infection. This encourages practitioners to establish discharge personalized care plan based on a multidimensional geriatric assessment and in parallel on clinical severity evaluation.


Sujets)
COVID-19 , Syndrome de fatigue chronique , Fragilité , Activités de la vie quotidienne , Sujet âgé , COVID-19/complications , COVID-19/thérapie , Syndrome de fatigue chronique/complications , Études de suivi , Personne âgée fragile , Fragilité/complications , Fragilité/diagnostic , Fragilité/épidémiologie , Évaluation gériatrique/méthodes , Humains , Études prospectives , Survivants
2.
Geriatr Psychol Neuropsychiatr Vieil ; 18(2): 141-148, 2020 Jun 01.
Article Dans Anglais | MEDLINE | ID: covidwho-874281

Résumé

Coronavirus disease 2019 (COVID-19) is a secondary infectious disease caused by severe acute respiratory syndrome coronavirus 2. The link between cardiovascular disease and COVID-19 appears to be twofold. First, some reports indicate that certain groups of patients are at greater risk of COVID-19, including patients with cardiovascular risk factors, pre-existing cardiovascular conditions and older patients. In addition, the outcomes these patients face are disproportionately more severe. Second, SARS-CoV-2 infection can be complicated by life-threatening acute cardiovascular diseases. Despite the rapid ongoing evolution of information about this pandemic, this review aims to highlight cardiovascular pathologies related to COVID-19 as either comorbidities, including concerns and uncertainty regarding the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on angiotensin conversion enzyme 2, or cardiovascular complications.


Sujets)
Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/thérapie , Infections à coronavirus/complications , Infections à coronavirus/thérapie , Pneumopathie virale/complications , Pneumopathie virale/thérapie , Angiotensin-converting enzyme 2 , Inhibiteurs de l'enzyme de conversion de l'angiotensine/usage thérapeutique , COVID-19 , Comorbidité , Humains , Pandémies , Peptidyl-Dipeptidase A/métabolisme , Système rénine-angiotensine/effets des médicaments et des substances chimiques
3.
Geriatr Psychol Neuropsychiatr Vieil ; 18(2): 125-133, 2020 06 01.
Article Dans Français | MEDLINE | ID: covidwho-611801

Résumé

The COVID-19 epidemic that started in November in China became a national epidemic from March 16, 2020 with the declaration of population containment in order to reduce the spread of the virus in France. From March 17 to March 27, 2020, the monitoring unit of the French society of geriatrics and gerontology decided to conduct a survey to analyze the implementation of the mobilization of geriatric units, given that this epidemic had shown that it resulted in excess mortality mainly among the elderly. The survey was able to bring together the response of 34 services, nine of which were located in a high epidemic cluster zone. Dedicated acute geriatric units for patients infected with COVID-19 were present in eight facilities, only outside the cluster zones. Nine geriatric follow-up and rehabilitation services were dedicated, an additional telemedicine activity concerned 35% of the facilities, and family listening and tablet communication facilities concerned 36% of the facilities. This survey is a snapshot of an initial moment in the epidemic. It provides an opportunity to describe the context in which this epidemic occurred in terms of geriatric policy, and to assess the responsiveness and inventiveness of these services in meeting the needs of the elderly.


Sujets)
Infections à coronavirus/thérapie , Gériatrie , Unités hospitalières/statistiques et données numériques , Pneumopathie virale/thérapie , Sujet âgé , Sujet âgé de 80 ans ou plus , COVID-19 , Infections à coronavirus/épidémiologie , Infections à coronavirus/mortalité , Femelle , France/épidémiologie , Besoins et demandes de services de santé , Humains , Mâle , Pandémies , Pneumopathie virale/épidémiologie , Pneumopathie virale/mortalité , Enquêtes et questionnaires , Télémédecine
4.
Geriatr Psychol Neuropsychiatr Vieil ; 2020.
Article | WHO COVID | ID: covidwho-315163

Résumé

The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The link between cardiovascular disease and COVID-19 appears to be twofold. First, some reports of data indicate that certain groups of patients are more at risk of COVID-19. This includes patients with cardiovascular risk factors or pre-existing cardiovascular conditions and older patients. In addition, these patients incur disproportionately worse outcome. Second, SARS-CoV2 infection can be complicated by life-threatening cardiovascular acute diseases. Despite the rapid evolution of data on this pandemic, this review aims to highlight the cardiovascular considerations related to COVID-19 whether as comorbidities including concerns and uncertainty regarding the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on angiotensin conversion enzyme 2 or related to acute cardiovascular complications.

SÉLECTION CITATIONS
Détails de la recherche